RE:Does Ritter Understand What is Has in RP-G28 ???Nice run up now that Ph 3 is fully enrolled. Preliminary results must be good for the run up to be this significant. I will add more when the run up dissipates following the next financing which will be needed to get the company through assessments and NDA approval. The run up is surprising since the news released ought to have been expected ... at least I expected as much ... and we already know it will work quite well on a good portion of the people.
I believe this will be the first Ph 3 test with results due in Q3 or Q4. I have not seen any details on whether a second Ph 3 test will be required and what its purpose would be or whether it would be required for an NDA submission or would it be considered add-on to expand the market or duration of the treatment to long term.
Hopefully we get these details in the next presentation update. Looks good but wishing I had loaded up in Dec ... just missed on the bid / ask at the time by a few pennies. I have a small core position that ensures some participation in the event of a run up.
More dilutive funds will be needed but the story long term should be a good one.
Ritter should (must) talk to Immuron to see if they combine their drugs will lactose intolerant people be able to take their dairy products (IMM-124E liver cancer, Travelan) since that will avert the risk allergy symptoms. Perhaps there is a simple and low cost test that could be done and my sense is there could be increased efficacy for Immuron products from the Ritter product for most everyone taking both drugs.
I wonder how the FDA manages dual drugs, and perhaps this could be done once revenue streams are on-line for both sides.
Mumbling to myself until investors wake up to this one ... LOL.